Cyramza (ramucirumab) 500 mg/50 mL concentrate for solution for infusion — original (Eli Lilly) Stomach cancer Targeted cancer therapy. Delivery of medications from Europe within 4-5 days, storage conditions observed, payment upon receipt. Order by calling +380996042415, Viber, WhatsApp.

Schulcancer

Cyramza in combination with paclitaxel is indicated for the treatment of adult patients with vulcan cancer on late stages or after adenocarcinoma of the gastroesophageal junction with progressive illness after chemotherapy with platinum and fluoropyrimidine (div. section “Pharmacological power").

Cyramza in the form of monotherapy is indicated for the treatment of adult patients with cancer of the scutum at an advanced stage or for adenocarcinoma of the gastroesophageal junction with progressive illness after chemotherapy from stagnation use of platinum and fluoropirimidins, unless combination therapy with paclitaxel is indicated (section “Pharmacological considerations”).

Colorectal cancer

Cyramza in combination with FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) whose disease has progressed within an hour or bevacizumab, oxaliplatin and fluoropyrimidine.

Non-clinical leg cancer (NDCLC)

Cyramza in combination with erlotinib is indicated as first-line therapy for adult patients with metastatic non-lichen cancer of the lungs with active mutations in the epidermal growth factor receptor (EGFR) (div. section “Pharmacological authorities”)

Cyramza in combination with docetaxel is indicated for the treatment of adult patients with locally expanded or metastatic non-lichen cancer of the leg with progressive disease after platinum-based chemotherapy.

Hepatocellular carcinoma (HCC)

Cyramza as monotherapy is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma or advanced stage hepatocellular carcinoma in whom alpha-fetoprotein is present. Blood serum level (AFP) ? 400 ng/ml, and after prior therapy with sorafenib.